Hasil Pencarian - Geoffrey R. Oxnard, MD

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC

    Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC oleh Lee S. Schwartzberg, MD, Gerald Li, PhD, Khaled Tolba, MD, Ariel B. Bourla, MD, PhD, Katja Schulze, PhD, Rujuta Gadgil, MS, Alexander Fine, PhD, Katherine T. Lofgren, PhD, Ryon P. Graf, PhD, Geoffrey R. Oxnard, MD, Davey Daniel, MD

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation

    Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation oleh Netta Mäkinen, PhD, Meng Zhou, PhD, Meredith Bemus, BS, Julius Nevin, BS, Anwesha Nag, PhD, Ruthia Chen, BA, Yolonda L. Colson, MD, PhD, Aaron R. Thorner, PhD, Geoffrey R. Oxnard, MD, Matthew Meyerson, MD, PhD, Lynette M. Sholl, MD

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer

    The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer oleh Barbara J. Gitlitz, MD, Silvia Novello, MD, PhD, Tiziana Vavalà, MD, Marisa Bittoni, PhD, Alicia Sable-Hunt, RN, MBA, Dean Pavlick, BS, Robert Hsu, MD, S. Lani Park, PhD, MPH, Ruthia Chen, BA, Matthew Cooke, BA, Amy Moore, PhD, Alexa B. Schrock, PhD, Joan H. Schiller, MD, Bonnie J. Addario, Geoffrey R. Oxnard, MD

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

    Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC oleh Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD

    Diterbitkan 2022-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

    SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping oleh Marissa N. Lawrence, BS, Rubii M. Tamen, BA, Pablo Martinez, MD, PhD, Alicia Sable-Hunt, RN, MBA, CCRA, Tony Addario, Pete Barbour, MS, MPM, PMP, Tristan Shaffer, BS, Seyed Ali Hosseini, MD, PhD, Caterina Bertucci, BS, MPA, Lee P. Lim, PhD, Fangxin Hong, PhD, Kesi Michael, BS, George R. Simon, MD, Jonathan W. Riess, MD, PhD, Mark M. Awad, MD, PhD, Geoffrey R. Oxnard, MD

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: